OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research note published on Wednesday. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

OPGN stock opened at $1.75 on Wednesday. OpGen has a twelve month low of $1.61 and a twelve month high of $11.20. The business has a 50 day moving average price of $1.96 and a two-hundred day moving average price of $3.19.

OpGen (NASDAQ:OPGN) last issued its earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. The company had revenue of $0.03 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new position in shares of OpGen, Inc. (NASDAQ:OPGN) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen at the end of the most recent reporting period. 2.68% of the stock is currently owned by institutional investors and hedge funds.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.